论文部分内容阅读
目的分析肺表面活性物质预防新生儿呼吸窘迫综合征临床应用效果。方法 120例早产儿随机分为观察组与对照组,各60例。观察组给予肺表面活性物质预防,对照组不使用任何药物预防,比较两组新生儿呼吸窘迫综合征发生情况。结果观察组新生儿呼吸窘迫综合征发生率为11.7%,对照组新生儿呼吸窘迫综合征发生率为38.3%,观察组新生儿呼吸窘迫综合征发生率显著低于对照组,差异有统计学意义(P<0.05);观察组发病时间长于对照组,差异有统计学意义(P<0.05);且观察组并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论肺表面活性物质预防新生儿呼吸窘迫综合征临床应用效果显著,值得在临床上推广。
Objective To analyze the clinical effect of pulmonary surfactant in preventing neonatal respiratory distress syndrome. Methods 120 cases of premature children were randomly divided into observation group and control group, each 60 cases. Observation group was given pulmonary surfactant prevention, the control group did not use any drug prevention, comparison of neonatal respiratory distress syndrome between the two groups. Results The incidence of neonatal respiratory distress syndrome was 11.7% in the observation group and 38.3% in the control group. The incidence of neonatal respiratory distress syndrome in the observation group was significantly lower than that in the control group (P <0.05). The onset time of the observation group was longer than that of the control group (P <0.05), and the complication rate of the observation group was lower than that of the control group (P <0.05). Conclusions Pulmonary surfactant is effective in preventing neonatal respiratory distress syndrome. It is worth to be popularized clinically.